Table 3.
Univariate Analysis Assessing Risk Factors for Severe Bronchiolitis (According to BCS ≥11 Points) and Differences Among Severe and Non‐Severe Group
| Non‐severe group (n = 328) | Severe group (n = 82) | P‐value | |
|---|---|---|---|
| Rhinovirus, n (%) | 91 (27.7) | 32 (39.0) | 0.041* |
| Age (months), median (IQR) | 1.8 (1.0–3.5) | 2.7 (1.1–5.0) | 0.037* |
| Temperature ≥38°C1, n (%) | 123 (37.5) | 44 (53.7) | 0.012* |
| Premature birth, n (%) | 41 (12.5) | 21 (25.6) | 0.009* |
| BPD, n (%) | 4 (1.2) | 6 (7.3) | 0.006* |
| CHD, n (%) | 7 (2.1) | 5 (6.1) | 0.050* |
| Severe neurologic impairment, n (%) | 0 | 4 (4.9) | 0.002* |
| HRSV, n (%) | 228 (69.5) | 52 (63.4) | 0.147 |
| HMPV, n (%) | 19 (5.8) | 7 (8.5) | 0.269 |
| HBoV, n (%) | 97 (29.6) | 22 (26.8) | 0.291 |
| Viral coinfection, n (%) | 155 (47.3) | 34 (41.5) | 0.414 |
| Dual infection HRSV–HRV, n (%) | 44 (13.4) | 12 (14.6) | 0.860 |
| Dual infection HRSV–HMPV, n (%) | 3 (0.9) | 1 (1.2) | 1.0 |
| Atopy, n (%) | 59 (18.0) | 18 (22.0) | 0.139 |
| Chromosomopathy, n (%) | 5 (1.5) | 3 (3.7) | 0.208 |
| Weight (kg), mean (IQR) | 4.7 (3.9–6.0) | 5.0 (3.8–6.7) | 0.395 |
| Days of coryza prior to admission, mean (IQR) | 3.5 (2.0–5.0) | 3.0 (2.0–5.0) | 0.515 |
BCS, bronchiolitis clinical score; IQR, interquartile range; BPD, bronchopulmonary dysplasia; CHD, congenital heart disease; HRSV, human respiratory syncytial virus; HMPV, human metapneumovirus; HBoV, human bocavirus.
Percentages refer to the column group.
At admission or the 48 hr before.
Statistical significant results.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.